13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q1 2025 · Filed May 13, 2025 · Accession 0000950123-25-004926
Total Value
$389.3M
Positions
12
Other Managers
0
Confidential Omitted
No
Holdings (12)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Arcellx, Inc. | ACLX | 2,346,630 | $153.9M | 39.54% |
| 2 | ARS Pharmaceuticals, Inc. | SPRY | 4,012,903 | $50.5M | 12.97% |
| 3 | Mineralys Therapeutics Inc. | MLYS | 3,127,933 | $49.7M | 12.76% |
| 4 | Zenas BioPharma, Inc | ZBIO | 4,911,539 | $38.8M | 9.97% |
| 5 | CRISPR Therapeutics AG | CRSP | 1,048,951 | $35.7M | 9.17% |
| 6 | Design Therapeutics, Inc. | DSGN | 6,526,476 | $25.2M | 6.47% |
| 7 | Alumis Inc. | ALMS | 1,959,896 | $12.0M | 3.09% |
| 8 | Oculis Holding AG | OCSAW | 322,500 | $6.1M | 1.58% |
| 9 | Nkarta, Inc. | NKTX | 3,333,333 | $6.1M | 1.58% |
| 10 | Oruka Therapeutics, Inc | ORKA | 430,330 | $4.4M | 1.13% |
| 11 | KALA Bio, Inc. | KALA | 598,940 | $3.4M | 0.88% |
| 12 | enGene Holdings Inc. | ENGNW | 747,750 | $3.3M | 0.86% |